Impax Laboratories Inc

Impax Laboratories — Merger or Acquisition (October 2017)

43 slides from Impax Laboratories's merger presentation, Oct 17, 2017

  1. Slide 1: A Strategic Combination for Long-Term Growth

    A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 + Filed by Amneal Pharmaceuticals LLC pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Impax Laboratories, Inc. Commission F

  2. Slide 2: Additional Information and Where to Find It

    Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitation material in respect of the proposed transaction bet

  3. Slide 3: Important Information for Investors and Shareholders

    Important Information for Investors and Shareholders Cautionary Note Regarding Forward-Looking Statements This communication includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking s

  4. Slide 4: Agenda

    Agenda TRANSACTION OVERVIEW & RATIONALE Paul Bisaro – Impax President & CEO COMBINED R&D & OPERATIONS Chintu Patel – Amneal Founder & Co-CEO AMNEAL OVERVIEW & COMMERCIAL OPERATIONS Chirag Patel – Amneal Founder & Co-CEO COMBINED FINANCIAL PROFILE Bryan Reasons – Impax CFO 1 2 3 4 5 CLOSING REMARKS P

  5. Slide 5: Transaction Overview & Rationale

    Transaction Overview & Rationale 1 Paul BISARO Impax President & CEO

  6. Slide 6: A Strategic Combination for Long-Term Growth

    A Strategic Combination for Long-Term Growth Per Last Twelve Months IMS Gross Revenues as of June 2017. Includes expected Year 1 run-rate synergies. See slide 20 for detail. In addition to the previously announced Impax standalone cost savings initiatives. Expanded Portfolio to Drive Growth Creates

  7. Slide 7: Combination Fuels Long-Term Growth

    Combination Fuels Long-Term Growth Estimated Revenue ($billions) Estimated Adjusted EBITDA(1) ($billions) Double-Digit Revenue & Adjusted EBITDA Growth Projected Over Next 3 Years Driven by a Diversified Portfolio of Generic Products Filed at FDA 2017E includes expected Year 1 run-rate synergies. 20

  8. Slide 8: Transaction Overview & Terms; NewCo Leadership

    NewCo leadership Chirag Patel and Chintu Patel will be Co-Chairmen of the Board Paul Bisaro will be CEO Bryan Reasons will be CFO NewCo Board of Directors Amneal Holdings will nominate six Board members, with Impax nominating five Current Impax Chairman Bob Burr to be lead outside director Amneal Ho

  9. Slide 9: Transaction Timeline

    Transaction Timeline Transaction timeline post-announcement: FTC / Hart-Scott-Rodino filings Minimal overlap of existing generic products Complete pre-close integration planning Estimated transaction close – First Half 2018 Timeline

  10. Slide 10: Poised for Success in Evolving Market Dynamics

    Poised for Success in Evolving Market Dynamics Filed generic pipeline contains industry leading, high-value product opportunities(1) across multiple dosage forms Fully diversified, cost efficient manufacturing and development capability provides access to high-value generic product opportunities Pos

  11. Slide 11: Amneal Overview & Commercial Operations

    Amneal Overview & Commercial Operations 2 Amneal Founder & Co-CEO PATEL Chirag

  12. Slide 12: Amneal Overview

    Amneal Overview Founded by Chirag Patel and Chintu Patel in 2002 Built on a unique culture driven by a passion for growth, entrepreneurship and quality U.S. focused with commercial presence in U.K. & Germany ~5,100 total employees Differentiated pipeline and robust organic R&D platform focused on co

  13. Slide 13: Augments Portfolio & Pipeline

    Augments Portfolio & Pipeline Expands combined generic portfolio to ~165 marketed generic product families(1) and generic pipeline to ~150 ANDAs filed(1) Accelerates Amneal’s entry into specialty pharmaceuticals and bolsters Impax’s generic pipeline Complements Amneal’s capabilities on multiple dosa

  14. Slide 14: Enhances Commercial Position

    Enhances Commercial Position #1 or #2 position in ~50% of commercial portfolio(1) Provides greater revenue diversification Top 5 generic product net revenue contribution ~25%(2) Opportunity to further capture long-term benefits of NewCo development engine NewCo has invested >$1 billion in R&D over t

  15. Slide 15: Combined R&D and Operations

    Combined R&D and Operations 3 Amneal Founder & Co-CEO PATEL Chintu

  16. Slide 16: Operational Excellence Accomplished

    Operational Excellence Accomplished Research and Development capabilities in the U.S., India and Ireland 7 R&D Centers co-located within global manufacturing footprint State-of-the-art manufacturing infrastructure in place: Cost efficient sites in India and the U.S., complemented by high-end manufac

  17. Slide 17: Diversified, High-Value Combined Pipeline

    Diversified, High-Value Combined Pipeline ~315 total projects in the combined pipeline, of which ~50%+ are high value opportunities(1) Expected annual pro forma combined R&D investment: ~10% of revenues COMBINED HISTORICAL ANDA FILINGS BY YEAR AND TYPE Data as of September 30, 2017. High value oppor

  18. Slide 18: Diverse and Expansive Manufacturing Technology Capabilities

    Diverse and Expansive Manufacturing Technology Capabilities INDIA LIQUID / TOPICAL TRANSDERMAL RESPIRATORY STERILE / ASEPTIC / SOD API HAYWARD, CA, BROOKHAVEN & HAUPPAUGE, NY BRANCHBURG & PISCATAWAY, NJ PISCATAWAY, NJ CASHEL, IRELAND AHMEDABAD & HYDERABAD, INDIA VIZAG & DEHEJ, INDIA Solutions, Suspe

  19. Slide 19: Combined Financial Profile

    Combined Financial Profile 4 Impax CFO REASONS Bryan

  20. Slide 20: Financially Compelling Combination

    Financially Compelling Combination Impax reaffirms standalone 2017E financial guidance NewCo expected to generate pro forma 2017E adjusted EBITDA of ~$600-$650 million(1) NewCo expected to generate pro forma 2018E adjusted EBITDA of ~$700-$750 million(1) Accretive to Impax’s adjusted EPS in the firs

  21. Slide 21: Fully Committed Financing in Place at Signing

    Expected interest rate of LIBOR + 350(1) All debt financed with no primary equity financing Projected strong adjusted EBITDA growth and free cash flow will enable deleveraging Expected net leverage at close of ~4.0x trailing 12 months pro forma adjusted EBITDA Combined balance sheet and strong cash

  22. Slide 22: Closing Remarks

    Paul BISARO Impax President & CEO Closing Remarks 5

  23. Slide 23: A Strategic Combination for Long-Term Growth

    A Strategic Combination for Long-Term Growth Per Last Twelve Months IMS Gross Revenues as of June 2017. Includes expected Year 1 run-rate synergies. See slide 20 for detail. In addition to the previously announced Impax standalone cost savings initiatives. Expanded Portfolio to Drive Growth Creates

  24. Slide 24: Q & A

    Q & A

  25. Slide 25: Appendix: Combined Company Information

    APPENDIX: COMBINED COMPANY INFORMATION

  26. Slide 26: Pro Forma Capitalization Table

    Pro Forma Capitalization Table ($ in millions) Impax cash balance as of 6/30/2017. Assumes 232 million shares issued to Amneal and closing share price of $19.95 for IPXL as of October 16, 2017. Includes expected Year 1 run-rate synergies. See slide 20 for detail.

  27. Slide 27: Industry-Leading Growth

    Industry-Leading Growth 2017E-2020E Revenue Growth 2017E-2020E EBITDA Growth Source: Peer group projections based on Factset consensus estimates as of September 25, 2017.

  28. Slide 28: Tangible Benefits from Increased Scale

    Tangible Benefits from Increased Scale Broader product portfolio and dosage form capabilities improve selling opportunities Leverage both companies’ strong relationships with customers Source: IMS Health. Pro forma for Fresenius’s acquisition of Akorn.

  29. Slide 29: Comprehensive Suite of Dosage Form Capabilities

    Comprehensive Suite of Dosage Form Capabilities Source: Competitive intelligence based on publicly available information. Full Suite of Capabilities in Generics = No Major Investment Anticipated Going Forward IR / ER Solids Injectables Oral Liquids Nasal Sprays Respiratory Ophthalmics Patches Topica

  30. Slide 30: Appendix: Amneal

    APPENDIX: AMNEAL

  31. Slide 31: Revenue Growing Through New Launches

    Revenue Growing Through New Launches New launches in 2015 - 2017 more than offset base business decline For the LTM 6/30/17 period, products launched in 2015 and later contributed ~43% of total revenue Revenue by Product Launch Vintage: LTM 6/30/17 ($ Millions) (1) Includes new product royalties.

  32. Slide 32: Strong Quality Systems & Track Record

    Strong Quality Systems & Track Record High quality product filings Strong quality systems supporting all aspects of development, analytical testing and manufacturing Solid compliance record year-after-year Ability to flexibly respond and adapt to FDA’s new systems and procedures Includes two inspect

  33. Slide 33: Broad Capabilities Across Dosage Forms

    Broad Capabilities Across Dosage Forms ORAL SOLIDS & LIQUIDS • IR / ER tablets • Hard Gelatin Capsules • Softgel Capsules • Hormonals • Controlled Substances • Suspensions / Solutions STERILE ASEPTICS • General Injectables • Oncology Injectables • Ophthalmics • Otics COMPLEX INJECTABLES • Peptides •

  34. Slide 34: History of Strong Financial Growth

    History of Strong Financial Growth Robust double-digit top-line growth driven by increasing market share in existing franchises and new product launches Despite higher R&D to support pipeline investments, adjusted EBITDA is projected to continue growing significantly Historical Revenue ($ millions)

  35. Slide 35: Amneal Selected Financial Data

    Amneal Selected Financial Data ($ in millions) Note: The financial information with respect to Amneal included herein has been derived from Amneal's historical financial statements, which were prepared and audited in accordance with U.S. GAAP and AICPA standards, but not in accordance with PCAOB sta

  36. Slide 36: Amneal Selected Financial Data (cont'd)

    Amneal Selected Financial Data (cont’d) ($ in millions) Note: The financial information with respect to Amneal included herein has been derived from Amneal's historical financial statements, which were prepared and audited in accordance with U.S. GAAP and AICPA standards, but not in accordance with

  37. Slide 37: Amneal Non-GAAP Financial Measures

    Amneal Non-GAAP Financial Measures ($ in millions) In 2016, Amneal entered into an agreement with a former development partner to settle a contract dispute. The total amount of the settlement paid by Amneal was $2.8 million. Reflects the impairment of a product purchased in 2013 based on an unfavora

  38. Slide 38: AP ; AX

    aa @ AP ; AX P aa | _——_ \ \

  39. Slide 39: Impax Overview

    Impax Overview Founded in 1994 U.S. focused with generic and specialty branded products ~1,400 total employees Generics business targets high-value solid oral and alternative dosage form ANDAs that are difficult to develop 20 products on file and 22 products in-development 74% of filed and in-develo

  40. Slide 40: Strong Diversified Generic Platform

    Strong Diversified Generic Platform Over two decades of experience in difficult to formulate generics Robust R&D infrastructure with a strong track record of success Diversified portfolio of ~74 commercial products with a mix of solid oral and alternate dosage forms Pipeline of ~40 filed and in deve

  41. Slide 41: Driving Growth with Specialty Brands

    Driving Growth with Specialty Brands Neurology-focused, specialty pharmaceutical company Rytary ER Capsules approved for treatment of Parkinson's disease, Post-encephalitic parkinsonism, and Parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication Approved in January

  42. Slide 42: Impax Financial Profile

    Impax Financial Profile Top-line growth driven by acquisitions and increasing generic and specialty product market share in existing franchises and new product launches Significant investments in R&D and Specialty Pharma sales and marketing impacted adjusted EBITDA Historical Revenue ($ millions) Hi

  43. Slide 43: Impax Non-GAAP Financial Measures

    Impax Non-GAAP Financial Measures ($ in millions)

Impax Laboratories — Merger or Acquisition (October 2017) on 6ix